logo-loader
viewZynerba Pharmaceuticals

Zynerba Pharmaceuticals anticipates data in late 2019 for its phase 3 cannabinoid drug

Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco.

Zynerba is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs.

Quick facts: Zynerba Pharmaceuticals

Price: 5.7 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $132.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BB Healthcare steadfast after rollercoaster 2019 for...

Should global politics and trade wars affect healthcare investments? Probably not - but they do, according to Investment Advisor and keen current affairs watcher at BB Healthcare Trust (LON:BBH) Paul Major. Major usefully highlights for Proactive London the folly of watching politics too...

2 hours, 50 minutes ago

2 min read